Abstract |
This review aimed to critically discuss the current protocols using gonadotropin-releasing hormone analogue (GnRHa) for the management of chemotherapy-induced premature ovarian failure. In in-vitro experiments, GnRHa retards doxorubicin-induced granulosa cell damage, suggesting an additional GnRH's activity to protect the gonads during chemotherapy through GnRH receptor-mediated mechanism(s). GnRHa acts to protect the gonads during radiation and/or chemotherapy by preferentially steering cells into cell cycle arrest with a decline in response to the chemotherapeutic agents. The ovarian protection by GnRHa co-treatment against chemotherapy can enable the preservation of future fertility in survivors and prevent the bone demineralisation and osteoporosis associated with hypooestrogenism and ovarian failure.
|
Authors | A Imai, T Furui |
Journal | Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
(J Obstet Gynaecol)
Vol. 27
Issue 1
Pg. 20-4
(Jan 2007)
ISSN: 0144-3615 [Print] England |
PMID | 17365452
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Gonadotropin-Releasing Hormone
|
Topics |
- Antineoplastic Agents
(adverse effects)
- Female
- Gonadotropin-Releasing Hormone
(analogs & derivatives, therapeutic use)
- Humans
- Infertility, Female
(etiology, prevention & control)
- Primary Ovarian Insufficiency
(chemically induced, complications, prevention & control)
|